GOG-0281

Terminated

Return to Protocol Table

A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients with Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer

Principal Investigator

David Gershenson

Status

Terminated

Open to Accrual

February 27, 2014

Temporarily Closed to Accrual

February 2, 2016

Open to Accrual

February 5, 2016

Closed to Accrual

April 10, 2018

Closed to Accrual & Treatment

July 14, 2025

Complete

July 14, 2025

Terminated

October 27, 2025


Disease Site

Gynecologic [GY] Ovarian

Phase

II/III

Developmental Therapeutics

No

Primary Objective

To estimate the progression-free survival (PFS) hazard ratio of trametinib compared to that of “commercially available therapies” consisting of one of five commercially available agents in women with recurrent low-grade serous carcinoma of the ovary or peritoneum previously treated with platinum-based chemotherapy.

Patient Population

Progression-free survival (PFS) hazard ratio of trametinib compared to that of “commercially available therapies” consisting of one of five commercially available agents in women with recurrent low-grade serous carcinoma of the ovary or peritoneum previously treated with platinum-based chemotherapy.

Target Accrual

250

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.


Patient Study Webpage

There is no available patient study webpage available for this trial at this time.